A new retrospective cohort study conducted in Dubai shows that the antiviral nirmatrelvir plus ritonavir, sold as Paxlovid, ...
Pfizer reported higher-than-expected profits driven by strong Paxlovid sales, offsetting a decline in COVID vaccine sales.
NEW YORK — A boost from Covid-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher ...
Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...
Pfizer reported higher-than-expected profit due to strong sales of COVID-19 treatment Paxlovid. Despite this success, the ...
Amid a looming standoff with activist investor Starboard Value, Pfizer fought back against accusations of underperforming by delivering double digit revenue growth over the third quarter and notchi | ...
The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, ...
Pfizer raised its full-year profit forecast after better-than-expected sales of its COVID-19 treatment helped it beat Wall Street estimates for third-quarter earnings on Tuesday.
Pfizer Q3 earnings beat expectations, driven by Paxlovid sales. Cost-saving goals aim for $4B by 2027 as Covid demand slows.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback